Legal & General Group PLC Spero Therapeutics, Inc. Transaction History

Legal & General Group PLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.68 - $2.2 $1,315 - $4,254	-1,934 Closed	0 $0
Q2 2022 Aug 22, 2022	SELL	$0.74 - $7.44 $478 - $4,813	-647 Reduced 25.07%	1,934 $1,000
Q1 2022 May 16, 2022	BUY	$7.87 - $15.15 $897 - $1,727	114 Added 4.62%	2,581 $22,000
Q3 2021 Nov 15, 2021	SELL	$13.03 - $19.51 $1,198 - $1,794	-92 Reduced 3.6%	2,467 $45,000
Q2 2021 Aug 12, 2021	BUY	$12.22 - $15.79 $4,765 - $6,158	390 Added 17.98%	2,559 $36,000
Q1 2021 May 17, 2021	SELL	$13.23 - $21.48 $108,896 - $176,801	-8,231 Reduced 79.14%	2,169 $32,000
Q4 2020 Feb 12, 2021	BUY	$11.65 - $22.07 $6,698 - $12,690	575 Added 5.85%	10,400 $202,000
Q3 2020 Nov 13, 2020	SELL	$8.96 - $14.12 $6,272 - $9,884	-700 Reduced 6.65%	9,825 $110,000
Q2 2020 Aug 14, 2020	BUY	$7.27 - $14.18 $64,383 - $125,578	8,856 Added 530.62%	10,525 $142,000
Q1 2020 May 14, 2020	SELL	$5.27 - $10.41 $2,397 - $4,736	-455 Reduced 21.42%	1,669 $13,000
Q3 2019 Nov 13, 2019	BUY	$9.01 - $12.55 $5,856 - $8,157	650 Added 44.1%	2,124 $23,000
Q1 2019 May 15, 2019	BUY	$6.26 - $13.31 $2,848 - $6,056	455 Added 44.65%	1,474 $19,000
Q4 2017 Feb 13, 2018	BUY	$10.43 - $14.75 $10,628 - $15,030	1,019	1,019 $12,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $33.3M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.